Arvind Madaan, MD
Allergy & Immunology · Charlottesville, VANPI 1699854307
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,208 of the $7,628 with a category attached, or 81.4%. It is spread thinly across 26 manufacturers, the largest accounting for just 16.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,976, 2.5 times the $788 reported in 2019.
Across 354 payments — averaging $21.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Blueprint Medicines Corporation$1K
- Regeneron Healthcare Solutions, Inc.$944
- Grifols USA, LLC$690
- GSK$647
- AstraZeneca$606
- Genentech USA, Inc.$602
- plus $3K from 20 others
Across 3 payments — averaging $3293.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$10K
What the payments were for
- Consulting fees$290%
- Speaking & faculty fees$1,26017%
- Food & beverage$6,20881%
- Education$1312%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Blueprint Medicines Corporation | 2 | $1,285 |
| Regeneron Healthcare Solutions, Inc. | 49 | $944 |
| Grifols USA, LLC | 40 | $690 |
| GSK | 39 | $647 |
| AstraZeneca | 33 | $606 |
| Genentech USA, Inc. | 28 | $602 |
| Kaleo, Inc. | 26 | $474 |
| Amgen | 23 | $416 |
| Novartis | 22 | $383 |
| ARS Pharmaceuticals Operations, Inc. | 32 | $348 |
| Sanofi | 18 | $346 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $281 |
| Biocryst US Sales Co., LLC | 6 | $132 |
| Ionis Pharmaceuticals, Inc. | 3 | $61 |
| CSL Behring | 2 | $59 |
| Alk-abello, Inc | 3 | $58 |
| Boehringer Ingelheim | 3 | $49 |
| Teva Pharmaceuticals USA, Inc. | 3 | $45 |
| Pharming Healthcare, Inc. | 2 | $43 |
| Pfizer | 2 | $35 |
| ADMA Biomanufacturing LLC | 1 | $29 |
| Hospira, Inc. | 1 | $24 |
| Aimmune Therapeutics, Inc. | 1 | $23 |
| Incyte Corporation | 1 | $18 |
| Optinose US, Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $13 |
How this compares
$7,628 in reported general payments places this provider in the 65th percentile of 133 allergy & immunology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 43 | $25,819 |
| Arnuity ElliptaFluticasone Furoate | 54 | $17,160 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $17,005 |
| Epinephrine | 61 | $10,110 |
| Qvar RedihalerBeclomethasone Dipropionate | 14 | $7,093 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 32 | $5,006 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $4,604 |
| Fluticasone Propionate HfaFluticasone Propionate | 14 | $2,735 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 14 | $2,373 |
| Montelukast Sodium | 197 | $2,176 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 35 | $1,838 |
| Ipratropium Bromide | 37 | $1,249 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $1,176 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 35 | $1,153 |
| Azelastine Hcl | 28 | $1,027 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Arnuity Ellipta, Breo Ellipta | $647 | $59,983123 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $45 | $7,09314 claims |
| AstraZenecaSymbicort | $606 | $4,60417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 133 allergy & immunology providers in Virginia.
Other allergy & immunology in Charlottesville
- Larry BorishCharlottesville$92K
- Emily McGowanCharlottesville$31K
- Charles LaneLynchburg$1.4M
- Jacqueline Eghrari-SabetVienna$1M
- Eric KarlinWilliamsburg$522K
- Nicholas RiderRoanoke$227K
- Courtney BlairMc Lean$139K
- Andrew KimFredericksburg$104K
- Behnam DaghighLeesburg$99K
- Ananth ThyagarajanBurke$97K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.